|
Dose levels at end of SR phase |
||||
| OROS® hydromorphone (N = 77) |
CR morphine (N = 86) |
|||
|
|
||||
| Dose level |
Dose (mg) every 24 hours |
Number of subjects (%) |
Dose (mg) every 12 hours |
Number of subjects (%) |
|
|
||||
| 1 |
16 |
22 (28.6) |
30 |
25 (29.1) |
|
|
||||
| 2 |
24 |
14 (18.2) |
60 |
23 (26.7) |
|
|
||||
| 3 |
32 |
18 (23.4) |
90 |
15 (17.4) |
|
|
||||
| 4 |
48 |
10 (13.0) |
120 |
13 (15.1) |
|
|
||||
| 5 |
72 |
5 (6.5) |
175 |
8 (9.3) |
|
|
||||
| 6 |
96 |
8 (10.4) |
260 |
2 (2.3) |
|
Abbreviations: CR, controlled-release; SR, sustained-release | ||||
Hanna et al. BMC Palliative Care 2008 7:17 doi:10.1186/1472-684X-7-17 |
||||